Cancer treatments rationed by authority

BMJ 1996; 313 doi: (Published 28 September 1996) Cite this as: BMJ 1996;313:774

The decision by a health authority to ration the use of two drugs for breast and ovarian cancer has been criticised.

Enfield-Haringey Health Authority sent out a letter to two trusts it has contracts with urging them to cut back on patients receiving paclitaxel (Taxol) and docetaxol (Taxotere). The authority, which is £1.7m ($2.6m) in deficit, said that it was taking the action because it had run out of money for treatment using the drugs. The …

View Full Text

Log in

Log in through your institution


* For online subscription